CliffBio
small molecule

LIKMEZ

METRONIDAZOLE

Loss of exclusivityOctober 2039latest FDA-listed patent expiry
CompanySAPTALIS PHARMACEUTICALS LLC

Drug detail

Brand nameLIKMEZ
Active ingredientMETRONIDAZOLE
Strength500MG/5ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2023
Marketing statusRX

Listed patents

PatentExpiresType
11541035October 2039product
12257236January 2039product

More from SAPTALIS PHARMACEUTICALS LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LIKMEZ patent cliff — loss of exclusivity October 2039 | CliffBio